Li B, Brady SW, Ma X*, Shen S, Zhang Y, Li Y, Szlachta K, Dong L, Liu Y, Yang F, Wang N, Flasch DA, Myers MA, Mulder HL, Ding L, Liu Y, Tian L, Hagiwara K, Xu K, Zhou X, Sioson E, Wang T, Yang L, Zhao J, Zhang H, Shao Y, Sun H, Sun L, Cai J, Sun HY, Lin TN, Du L, Li H, Rusch M, Edmonson MN, Easton J, Zhu X, Zhang J, Cheng C, Raphael BJ, Tang J, Downing JR, Alexandrov LB, Zhou BS, Pui CH, Yang JJ, Zhang J. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Next generation sequencing: variant calling; IGV-based variant inspection; whole-genome/exome analysis for mutations including copy number, loss of heterozygosity, structural variation, SNV/Indel; RNAseq based fusion analysis; bam/fastq operations including mapping and basic quality control; variant functional interpretation using data collected from patient cohort and molecular biology and genetics principles.